| # | Aladdin ID | Assay Type | Description | Organism | Compounds | Reference | BAO Format | Source | |
|---|---|---|---|---|---|---|---|---|---|
| 1. | ALA1805779 | B | Inhibition of human platelet cPLA2alpha assessed as inhibition of arachidonic acid production after 60 mins by UV-reverse phase HPLC analysis | Homo sapiens | 21 | ALA1799943 | assay format | Scientific Literature | |
| 2. | ALA1805780 | A | Metabolic stability in rat liver microsomes assessed as compound remaining after 30 mins by UV-reverse phase HPLC analysis | Rattus norvegicus | 20 | ALA1799943 | microsome format | Scientific Literature | |
| 3. | ALA1805781 | P | Thermodynamic solubility of the compound in phosphate buffer of pH 7.4 incubated for 20 hrs at room temperature by UV-reverse phase HPLC analysis | 20 | ALA1799943 | small-molecule physicochemical format | Scientific Literature | ||
| 4. | ALA1805782 | P | Partition coefficient, log P of the compound by reverse phase HPLC analysis | 21 | ALA1799943 | small-molecule physicochemical format | Scientific Literature | ||
| 5. | ALA1805783 | B | Inhibition of TPA-induced cPLA2alpha activity in human platelets assessed as inhibition of arachidonic acid production after 60 mins by UV-reverse phase HPLC analysis | Homo sapiens | 3 | ALA1799943 | assay format | Scientific Literature | |
| 6. | ALA1805784 | B | Inhibition of rat brain iPLA2 assessed as 10-pyren-1-yldecanoic acid release using 1-palmitoyl-2-(10-pyren-1-yldecanoyl)-sn-glycero-3-phosphocholine as substrate at 10 uM by UV-reverse phase HPLC analysis | Rattus norvegicus | 2 | ALA1799943 | assay format | Scientific Literature | |
| 7. | ALA1805785 | B | Inhibition of pig pancreas group 1B sPLA2 assessed as release of oleic acid using 2-oleoyl-1-palmitoyl-sn-glycero-3-phospho-rac-(1-glycerol) (ammonium salt) as substrate at 10 uM by UV-reverse phase HPLC analysis | Sus scrofa | 2 | ALA1799943 | single protein format | Scientific Literature | |
| 8. | ALA1805786 | A | Drug level in C57Bl6 mouse plasma at 100 mg/kg, po after 1 hr by HPLC analysis | Mus musculus | 2 | ALA1799943 | organism-based format | Scientific Literature | |
| 9. | ALA1805787 | A | Drug level in C57Bl6 mouse plasma at 100 mg/kg, po after 2 hrs by HPLC analysis | Mus musculus | 2 | ALA1799943 | organism-based format | Scientific Literature | |
| 10. | ALA1805790 | A | Drug level in C57Bl6 mouse plasma assessed as 3-(5-carboxypentanoyl)-1-(2-hydroxy-3-(4-octylphenoxy)propyl)-1H-indole-5-carboxylic acid at 100 mg/kg, po after 1 hr by HPLC analysis | Mus musculus | 1 | ALA1799943 | organism-based format | Scientific Literature | |
| 11. | ALA1805791 | A | Drug level in C57Bl6 mouse plasma assessed as 3-(5-carboxypentanoyl)-1-(2-hydroxy-3-(4-octylphenoxy)propyl)-1H-indole-5-carboxylic acid at 100 mg/kg, po after 2 hrs by HPLC analysis | Mus musculus | 1 | ALA1799943 | organism-based format | Scientific Literature | |
| 12. | ALA1805793 | A | Drug level in C57Bl6 mouse bile at 100 mg/kg, po after 2 hrs by HPLC analysis | Mus musculus | 1 | ALA1799943 | organism-based format | Scientific Literature | |
| 13. | ALA1805795 | A | Drug level in C57Bl6 mouse bile at 100 mg/kg, po after 2 hrs by HPLC analysis in presence of Helix pomatia beta-glucuronidase HP2 | Mus musculus | 1 | ALA1799943 | organism-based format | Scientific Literature | |
| 14. | ALA1805797 | A | Drug level in C57Bl6 mouse intestine assessed per gut at 100 mg/kg, po after 2 hrs by HPLC analysis | Mus musculus | 1 | ALA1799943 | organism-based format | Scientific Literature | |
| 15. | ALA1805799 | A | Drug level in C57Bl6 mouse intestine assessed per gut at 100 mg/kg, po after 2 hrs by HPLC analysis in presence of Helix pomatia beta-glucuronidase HP2 | Mus musculus | 2 | ALA1799943 | organism-based format | Scientific Literature | |
| 16. | ALA4000775 | A | Metabolic stability in CD-1 mouse liver S9 fraction assessed as UGT-mediated glucuronidation of compound by measuring compound remaining at 5 uM preincubated for 3 mins followed by UDPGA addition measured after 60 mins by HPLC/MS analysis | Mus musculus | 12 | ALA4000171 | assay format | Scientific Literature | |
| 17. | ALA4000776 | A | Metabolic stability in CD-1 mouse liver S9 fraction assessed as NADPH CYP450 reductase-mediated compound metabolism by measuring compound remaining in presence of NADPH at 20 uM after 30 mins by HPLC method | Mus musculus | 11 | ALA4000171 | assay format | Scientific Literature | |
| 18. | ALA4000777 | P | Thermodynamic solubility of the compound in phosphate buffer at pH 7.4 at 1 mg sonicated for 10 mins measured after 20 hrs by reverse phase HPLC analysis | 12 | ALA4000171 | small-molecule physicochemical format | Scientific Literature | ||
| 19. | ALA4000778 | B | Inhibition of human platelet cytosolic phospholipase alpha-2 using 1-stearoyl-2-arachidonoyl-sn-glycero-3-phosphocholine/1,2-dioleoyl-sn-glycerol as substrate after 60 mins by UV-HPLC method | Homo sapiens | 12 | ALA4000171 | assay format | Scientific Literature | |
| 20. | ALA4000779 | A | Metabolic stability in rat liver microsomes assessed as NADPH CYP450 reductase-mediated compound metabolism by measuring compound remaining in presence of NADPH at 20 uM after 30 mins by HPLC | Rattus norvegicus | 11 | ALA4000171 | assay format | Scientific Literature |
The page will load shortly, Thanks for your patience!